IN EARLY STAGE HER2+ BREAST CANCER
NERLYNX is your next step to further reduce the risk of recurrence following trastuzumab-based therapy

NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

Nerlynx in HER2+, HER+ patients. 51% reduction in risk of recurrence vs placebo at 2 years and 40% reduction in risk of recurrence vs placebo in 5 years. See all efficacy results 1,† 2,†,‡

DOSING AND ADMINISTRATION GUIDE

Learn about dose modifications, antidiarrheal prophylaxis, and drug interactions with NERLYNX.

Download

MANAGING ADVERSE EVENTS

Prophylaxis reduces incidence and severity of diarrhea1

Loperamide prophylaxis guidance

Quick links

Full Prescribing Information

Enrollment Form

Specialty Pharmacy List

Select IMPORTANT SAFETY INFORMATION

The most common adverse reactions (⪰ 5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased and urinary tract infection.

Please see additional IMPORTANT SAFETY INFORMATION below.

HER2: human epidermal growth factor receptor 2; HR: hormone receptor

Recurrence is defined as an invasive disease event or death.

93% of the patients with HER2+, HR+ disease had concomitant endocrine therapy.

Results of ExteNET are supported by an exploratory analysis of 5-year follow-up with 74.5% (2117/2840) of patients reconsented.

IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions (≥ 5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and www.NERLYNX.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

For Full Prescribing Information, please click here.